Author: Mazilu, Laura; Katsiki, Niki; Nikolouzakis, Taxiarchis Konstantinos; Aslanidis, Minas I.; Lazopoulos, George; Kouretas, Dimitrios; Tsatsakis, Aristidis; Suceveanu, Andra-Iulia; Stoian, Anca-Pantea; Parepa, Irinel-Raluca; Voinea, Felix; Suceveanu, Adrian Paul; Arsene, Andreea Letiția; Velescu, Bruno Ștefan; Vesa, Cosmin; Nitipir, Cornelia
Title: Thrombosis and Haemostasis challenges in COVID-19 – Therapeutic perspectives of heparin and tissue-type plasminogen activator and potential toxicological reactions-a mini review Cord-id: kvprwlsz Document date: 2021_1_6
ID: kvprwlsz
Snippet: The coronavirus disease (COVID)-19 pandemic is a major challenge for the health systems worldwide. Acute respiratory distress syndrome (ARDS), is one of the most common complications of the COVID-19 infection. The activation of the coagulation system plays an important role in the pathogenesis of ARDS. The development of lung coagulopathy involves thrombin generation and fibrinolysis inhibition. Unfractionated heparin and its recently introduced counterpart low molecular weight heparin (LMWH), a
Document: The coronavirus disease (COVID)-19 pandemic is a major challenge for the health systems worldwide. Acute respiratory distress syndrome (ARDS), is one of the most common complications of the COVID-19 infection. The activation of the coagulation system plays an important role in the pathogenesis of ARDS. The development of lung coagulopathy involves thrombin generation and fibrinolysis inhibition. Unfractionated heparin and its recently introduced counterpart low molecular weight heparin (LMWH), are widely used anticoagulants with a variety of clinical indications allowing for limited and manageable physio-toxicologic side effects while the use of protamine sulfate, heparin's effective antidote, has made their use even safer. Tissue-type plasminogen activator (tPA) is approved as intravenous thrombolytic treatment. The present narrative review discusses the use of heparin and tPA in the treatment of COVID-19-induced ARDS and their related potential physio-toxicologic side effects. The article is a quick review of articles on anticoagulation in COVID infection and the potential toxicologic reactions associated with these drugs.
Search related documents:
Co phrase search for related documents- acute ards respiratory distress syndrome and local fibrinolysis: 1, 2
- acute ards respiratory distress syndrome and local fibrinolysis promote: 1
- acute ards respiratory distress syndrome and low molecular: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
- acute ards respiratory distress syndrome and low molecular lmwh weight heparin: 1, 2, 3, 4, 5, 6
- acute phase and lmwh weight heparin: 1, 2
- acute phase and low molecular: 1, 2, 3, 4, 5, 6, 7, 8
- acute phase and low molecular lmwh weight heparin: 1, 2
- acute respiratory and lmwh therapy: 1, 2
- acute respiratory and lmwh weight heparin: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
- acute respiratory and local fibrinolysis: 1, 2
- acute respiratory and local fibrinolysis promote: 1
- acute respiratory and local guideline: 1
- acute respiratory and low consumption: 1, 2, 3, 4, 5, 6
- acute respiratory and low molecular: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory and low molecular lmwh weight heparin: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
- lmwh prophylactic treatment and low molecular: 1, 2, 3, 4
- lmwh prophylactic treatment and low molecular lmwh weight heparin: 1, 2
- lmwh therapy and low molecular: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
- lmwh therapy and low molecular lmwh weight heparin: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
Co phrase search for related documents, hyperlinks ordered by date